Clinical trials: SCLC,Extensive Stage
SCLC, Extensive Stage
Nanocrystalline Megestrol + Immunochemo As 1st-Line for ES-SCLC Cachexia
This study hypothesizes that nanocrystalline megestrol acetate can improve the cachexia condition in patients and enhance the efficacy of immunochemotherapy regimens.
- Trial name
- NCT06793228
- Testing
- Nanocrystalline Megestrol Acetate, Tislelizumab, PTOC
- Where
- 4 sites in China
- Volunteers
- 250 people
- Sponsor
- Henan Cancer Hospital
Small Cell Lung Cancer, SCLC
MOnaliZumab in Combination With durvAlumab (MEDI4736) for tRreatmenT of Small Cell Lung Cancer
This study has 2 cohorts: MOZART-ES cohort (for extensive-stage SCLC) and MOZART-LS cohort (for limited-stage SCLC). MOZART-ES cohort: Study treatment will consist of a platinum drug (carboplatin or cisplatin per investigator's…
- Conditions
- Small Cell Lung Cancer, SCLC, Extensive Stage Small Cell Lung Cancer, Limited Stage Small-Cell Lung Cancer
- Trial name
- MOZART (NCT05903092)
- Testing
- Durvalumab, Monalizumab, Carboplatin or Cisplatin
- Where
- 4 sites in United States
- Volunteers
- 84 people
- Sponsor
- Hirva Mamdani
Cancer
E-MOSAIC Electronic Tool to Monitor Symptoms
RATIONALE: A hand held electronic tool used to monitor symptoms and assess quality of life may improve communication between patients and their doctors and improve the ability to plan treatment for patients with advanced cancer…
- Trial name
- NCT00477919
- Where
- 7 sites in Switzerland
- Volunteers
- 264 people
- Sponsor
- Swiss Cancer Institute
Small Cell Lung Cancer
Tarlatamab (AMG 757) Expanded Access Protocol for Advanced Small Cell Lung Cancer
The primary objective of the study is to provide expanded access to and characterize the safety profile of tarlatamab in participants with advanced small cell lung cancer (SCLC) after two or more prior lines of treatment…
- Trial name
- NCT06064500
- Testing
- Tarlatamab
- Where
- 23 sites in United States, Brazil and 2 more
- Sponsor
- Amgen
Small Cell Lung Cancer
Trial of BMS-986012 in Combination With Platinum and Etoposide
The purpose of this this study is to administer BMS-986012 in Combination with Platinum and Etoposide as First-line Therapy in Extensive Small Cell Lung Cancer.
- Trial name
- NCT02815592
- Testing
- BMS-986012, Cisplatin, Etoposide
- Where
- 4 sites in Spain
- Volunteers
- 12 people
- Sponsor
- Bristol-Myers Squibb
Small Cell Lung Carcinoma
REAL-WORLD DURVALUMAB IN EXTENSIVE-STAGE SMALL CELL LUNG CANCER
Primary lung cancer is one of the most common malignancies and causes of cancer-related death worldwide [Passiglia et al., 2019; Bade and Dela Cruz, 2020].
- Trial name
- ARAL (NCT06826677)
- Testing
- Durvalumab
- Where
- 11 sites in Italy
- Volunteers
- 71 people
- Sponsor
- AstraZeneca
Extensive Stage Small Cell Lung Cancer
CCI-779 in Treating Patients With Extensive-Stage Small Cell Lung Cancer
Randomized phase II trial to compare the effectiveness of different doses of CCI-779 in treating patients who have extensive-stage small cell lung cancer.
- Trial name
- NCT00028028
- Testing
- temsirolimus, pharmacological study, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- National Cancer Institute (NCI)
Small Cell Lung Cancer
A Study of IMGN901 for Patients With Advanced Solid Tumors and Extensive Stage Small Cell Lung Cancer
The purpose of this study is to test safety and efficacy of this combination treatment (IMGN901, carboplatin and etoposide) in patients with solid tumors and extensive stage small cell lung cancer.
- Trial name
- NCT01237678
- Testing
- IMGN901, Carboplatin and Etoposide
- Where
- 48 sites in United States, Canada and 2 more
- Volunteers
- 181 people
- Sponsor
- ImmunoGen, Inc.
Small Cell Lung Cancer (SCLC), SCLC, Extensive Stage
A Study of Bemotuzumab Plus Chemotherapy and Anlotinib Induction Followed by Bemotuzumab, Anlotinib and Consolidative Thoracic Radiotherapy in Extensive-Stage Small Cell Lung Cancer
This is a phase II study evaluating a new combination therapy for untreated extensive-stage small cell lung cancer. The treatment involves an initial phase with the drug Bemotuzumab plus standard chemotherapy and anlotinib…
- Trial name
- NCT07358676
- Testing
- Bemotuzumab + Anlotinib + Chemotherapy + Radiotherapy
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Extensive Small Cell Lung Cancer
A Phase II Study of QL1706 With Anti-angiogenesis Therapy and Chemotherapy in Extensive-stage Small Cell Lung Cancer.
This single-arm, open-label, Phase II study assesses first-line QL1706 + bevacizumab (anti-VEGF) + platinum/etoposide chemotherapy to treat naïve ES-SCLC patients.The main questions it aims to answer are: Evaluate efficacy and…
- Trial name
- QL1706 (NCT07083375)
- Testing
- QL1706 , bevacizumab, etoposide , cisplatin or carboplatin
- Where
- China
- Volunteers
- 56 people
- Sponsor
- Zhijie Wang
Extensive-stage Small Cell Lung Cancer
Phase II Study of Irinotecan and Cisplatin in Extensive-stage Small Cell Lung Cancer
Patients with untreated extensive-stage small cell lung cancer(SCLC) were randomly assigned to receive either irinotecan/cisplatin (IP) or etoposide/cisplatin(EP), The association of efficacy and toxicity of IP regimen was…
- Trial name
- NCT02323737
- Testing
- Irinotecan and cisplatin, Etoposide and cisplatin
- Where
- China
- Volunteers
- 62 people
- Sponsor
- Chinese Academy of Medical Sciences
Platinum-Resistant Lung Small Cell Carcinoma, Platinum-Sensitive Lung Small Cell Carcinoma
Durvalumab and Lurbinectedin for the Treatment of Relapsed or Refractory Small Cell Lung Cancer
This phase II trial studies the effects of durvalumab and lurbinectedin in treating patients with extensive stage small cell lung cancer that has come back (relapsed) or has not responded to previous treatment with chemotherapy…
- Conditions
- Platinum-Resistant Lung Small Cell Carcinoma, Platinum-Sensitive Lung Small Cell Carcinoma, Recurrent Extensive Stage Lung Small Cell Carcinoma, Refractory Extensive Stage Lung Small Cell Carcinoma
- Trial name
- NCT04607954
- Testing
- Durvalumab, Lurbinectedin
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- Mayo Clinic
Extensive Stage Small Cell Lung Cancer
Nab-paclitaxel Versus Topotecan As Second-Line Treatment for Patients With Extensive Stage Small Cell Lung Cancer
The purpose of this study is to compare the efficacy and safety of nab-paclitaxel with topotecan as second-line treatment for patients with extensive stage small cell lung cancer.
- Trial name
- NCT04213937
- Testing
- nab-paclitaxel, Topotecan
- Where
- China
- Volunteers
- 386 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Extensive-stage Small-cell Lung Cancer
Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer
This is a Phase III, multisite, randomized, double-blinded study to investigate pumitamig (BNT327) combined with chemotherapy (etoposide/carboplatin) compared to atezolizumab combined with chemotherapy (etoposide/carboplatin) for…
- Trial name
- NCT06712355
- Testing
- Pumitamig, Atezolizumab, Etoposide
- Where
- 225 sites in United States, Australia and 12 more
- Volunteers
- 621 people
- Sponsor
- BioNTech SE
Lung Cancer
Palliative 3-Dimensional Conformal Radiation Therapy in Reducing Radiation Side Effects in Patients With Lung Cancer. ICORG 06-34
RATIONALE: 3-dimensional conformal radiation therapy may lessen side effects caused by palliative radiation therapy and improve the quality of life of patients with lung cancer.
- Trial name
- NCT01176487
- Testing
- questionnaire administration, quality-of-life assessment, 3-dimensional conformal radiation therapy
- Where
- 2 sites in Ireland
- Volunteers
- 40 people
- Sponsor
- Cancer Trials Ireland
Breast Cancer, Colorectal Cancer
Treated Blood Cells, Cyclophosphamide, Fludarabine Phosphate, and Aldesleukin in Treating Patients With Cancer
RATIONALE: Placing a gene into T cells may improve the body's ability to recognize cancer cells and build an immune response to fight cancer.
- Conditions
- Breast Cancer, Colorectal Cancer, Gastric Cancer, Lung Cancer
- Trial name
- NCT01212887
- Testing
- MFE23 scFv-expressing autologous anti-CEA MFEz T lymphocytes, aldesleukin, cyclophosphamide
- Where
- United Kingdom
- Volunteers
- 14 people
- Sponsor
- Cancer Research UK
Small Cell Lung Cancer
Toripalimab in Combination With Platinum Plus Etoposidein Patients With Extensive-Stage Small Cell Lung Cancer
This is a phase III, multicenter, double-blinded, placebo-controlled study of platinum（Cisplatin or Carboplatin） plus etoposide with or without toripalimab as first Line therapy in patients with extensive stage small cell lung…
- Trial name
- NCT04012606
- Where
- China
- Volunteers
- 442 people
- Sponsor
- Shanghai Junshi Bioscience Co., Ltd.
SCLC,Extensive Stage
Pembrolizumab and Olaparib Treatment of Extensive Small Cell Lung Cancer (ES-SCLC)
This is an open-label, single arm, phase 2 trial enrolling patients with untreated Extensive-Stage Small-Cell Lung Cancer (ES SCLC), with a strong translational attitude.
- Trial name
- THOR (NCT05623319)
- Testing
- Pembrolizumab/Olaparib
- Where
- 12 sites in Italy
- Volunteers
- 60 people
- Sponsor
- Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Apatinib in Maintenance Treatment
The Efficacy and Safety of Apatinib Monotherapy in Maintenance Treatment of Extensive-stage Small-cell Lung Cancer
52 patients with extensive-stage small-cell lung cancer and without progression after completing chemotherapy, will receive apatinib monotherapy as maintenance therapy.
- Trial name
- NCT03129698
- Testing
- Apatinib
- Where
- China
- Volunteers
- 52 people
- Sponsor
- Junling Li
Small-Cell Lung Cancer
A Phase III, Open-Label Study of Maintenance Lurbinectedin in Combination With Atezolizumab Compared With Atezolizumab in Participants With Extensive-Stage Small-Cell Lung Cancer
Study GO43104 is a Phase III, randomized, open-label, multicenter study of lurbinectedin in combination with atezolizumab compared with atezolizumab alone administered as maintenance therapy in participants with extensive-stage…
- Trial name
- IMforte (NCT05091567)
- Testing
- Atezolizumab, Lurbinectedin, Carboplatin
- Where
- 93 sites in United States, Belgium and 11 more
- Volunteers
- 660 people
- Sponsor
- Hoffmann-La Roche